Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01711021 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate Safety & Efficacy of d-Amphetamine Transdermal System vs Placebo in Children & Adolescents With ADHD
A Phase 2 study, sponsored by Noven Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 110
- Enrollment target
NCT01711021: Completed Phase 2 study, sponsored by Noven Pharmaceuticals.
NCT01711021 is a Phase 2 study that has completed, run by Noven Pharmaceuticals. The registered enrollment target is 110 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (17% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01711021, a Phase 2 study, has completed, sponsored by Noven Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 110 participants
- Enrollment target
Study Summary
This study will evaluate safety and efficacy of d-Amphetamine Transdermal System for the treatment of Attention Deficit Hyperactivity Disorder in children and adolescents.
Interventions
- DRUG Placebo patch
- DRUG d-Amphetamine Transdermal Patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2012-10 |
| Est. Completion | 2013-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01711021
The ClinicalTrials.gov registry entry for NCT01711021 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (17% lower). The listed sponsor is Noven Pharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo patch is the first listed.
NCT01711021 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01711021 about?
NCT01711021 is a clinical study titled "Study to Evaluate Safety & Efficacy of d-Amphetamine Transdermal System vs Placebo in Children & Adolescents With ADHD". This study will evaluate safety and efficacy of d-Amphetamine Transdermal System for the treatment of Attention Deficit Hyperactivity Disorder in children and adolescents.
What is the current status of trial NCT01711021?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 110 participants. The study started on 2012-10. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01711021?
The interventions under investigation include: Placebo patch (DRUG), d-Amphetamine Transdermal Patch (DRUG).
Who is sponsoring clinical trial NCT01711021?
This trial is sponsored by Noven Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.